Medications

What is Retatrutide? A New Triple-Hormone Weight Loss Medication Explained

If you've been following the evolution of weight loss medications, you've likely heard about GLP-1 drugs like semaglutide and tirzepatide. But there's a new medication in development that's generating significant excitement in the medical community: retatrutide. While not yet FDA-approved, this investigational drug is showing remarkable promise in clinical trials, with some participants experiencing weight loss that surpasses even the most effective medications currently available.

Understanding what retatrutide is and how it works can help you stay informed about the future of metabolic health treatment, even if it's not yet available for prescription.

What Is Retatrutide?

Retatrutide is an investigational weight loss medication currently in Phase 3 clinical trials. Unlike current GLP-1 receptor agonists, retatrutide is what researchers call a "triple agonist" because it activates three different hormone receptors in your body simultaneously.

Specifically, retatrutide targets the GLP-1 receptor (like semaglutide), the GIP receptor (like tirzepatide), and adds a third target: the glucagon receptor. This triple-action approach represents a new frontier in weight management medication.

The drug is being developed by Eli Lilly, the same pharmaceutical company behind Mounjaro and Zepbound (tirzepatide). It's administered as a once-weekly injection, similar to other weight loss medications you may already be familiar with.

How Does Retatrutide Work?

To understand retatrutide, it helps to break down how each of its three targets contributes to weight loss and metabolic health.

GLP-1 Receptor Activation

The GLP-1 component works just like semaglutide (Wegovy, Ozempic). It slows digestion, reduces appetite, and helps regulate blood sugar levels. This is the mechanism that's already proven highly effective in current weight loss medications.

GIP Receptor Activation

The GIP component, which is also found in tirzepatide, may improve how your body processes fat and sugar while potentially enhancing the GLP-1 effects. Research suggests GIP plays an important role in metabolism and insulin sensitivity.

Glucagon Receptor Activation

This is where retatrutide differs from everything currently available. Glucagon typically raises blood sugar, but when activated in combination with GLP-1 and GIP, it appears to increase energy expenditure and fat burning. Think of it as potentially boosting your metabolic rate while the other two components help reduce appetite.

Together, these three mechanisms create a comprehensive approach to weight management that addresses multiple pathways simultaneously.

What Do Clinical Trials Show?

The results from retatrutide's Phase 2 clinical trials, published in 2023, captured significant attention in the medical community.

In a 48-week study, participants taking the highest dose of retatrutide (12 mg) lost an average of 24% of their body weight. For someone weighing 250 pounds, that would represent approximately 60 pounds of weight loss.

To put this in perspective, current FDA-approved medications show average weight loss of about 15% for semaglutide and up to 22% for tirzepatide at their highest doses. Retatrutide's results suggest it could potentially offer even greater benefits, though it's important to remember these are still investigational findings.

Participants also experienced improvements in metabolic markers including blood sugar levels, cholesterol, and blood pressure. The medication appeared to be generally well-tolerated, with side effects similar to other GLP-1 medications.

Gender Considerations in Clinical Trials

While detailed gender-specific data from retatrutide trials is still being analyzed, research on similar medications has shown that women and men may experience slightly different responses. Women often report more gastrointestinal side effects initially, while both genders typically see significant weight loss results. As more data becomes available, we'll better understand how retatrutide specifically affects different populations.

When Will Retatrutide Be Available?

Retatrutide is currently in Phase 3 clinical trials, which is the final stage before a manufacturer can apply for FDA approval. If these trials continue to show positive results, the earliest it might become available for prescription would likely be 2026 or 2027.

The FDA approval process is thorough and can take considerable time, as it should. Any new medication needs to demonstrate not just effectiveness, but also safety across diverse populations and extended use periods.

How Does Retatrutide Compare to Current Options?

While we can't make definitive comparisons until retatrutide is fully studied and approved, here's what we know so far:

Each step forward has added another mechanism of action, and with each addition, we've seen improved results in clinical trials.

What Are the Potential Side Effects?

Because retatrutide is still investigational, we don't have complete safety data. However, in clinical trials so far, side effects have been similar to other GLP-1 medications:

Most side effects were mild to moderate and decreased over time as participants adjusted to the medication. However, as with any medication, some people discontinued treatment due to side effects.

What Should You Do Now?

If you're currently struggling with weight management, you don't need to wait for retatrutide to take action. The medications available today—semaglutide and tirzepatide—are already producing life-changing results for many people.

These FDA-approved options have extensive safety data, proven effectiveness, and are accessible right now through telehealth platforms and traditional healthcare providers.

Starting your weight loss journey today with a proven medication is better than waiting years for a potentially slightly more effective option that may or may not work better for your individual body.

From the Ozari Care Team

While retatrutide represents an exciting development in metabolic medicine, the most important medication is the one you'll actually take consistently. Current GLP-1 and dual-agonist medications are highly effective, and starting treatment now means you're not postponing your health goals for an uncertain future. The best approach is always the one that fits your life today.

At Ozari Health we offer compounded Semaglutide and Tirzepatide as low as $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026